The binding constraints on biotech innovation are not just AI capability but rather cycle time—the speed at which research hypotheses can be tested—and biological processes have natural speed limits that AI cannot overcome, though synthetic biology companies finding ways to compress cycle times maximize AI's leverage.

causalpending

Speaker

Sam Altman

Evidence Quote

“as you mentioned there still will be like the rate limit of like bio has to run at its own thing and human Trials take however long they take and that's so I think an interesting cut of this is like where can you avoid that like where are the the synthetic bio companies that I've seen that have been most interesting are the ones that find a way to like make the cycle time super fast um and that that benefits like an AI That's giving you a lot of good ideas but you've still got to test them”

Source

OpenAI CEO Sam Altman | AI for the Next Era— Greylock
Created: 8/10/2026, 10:47:22 PM

Your notes

Loading notes...